As the world is eager to return to normal life after more than a year of pandemic, countries are racing to provide vaccines to slow — and hopefully prevent — the spread of the virus. coronavirus.
The success of this will depend on a range of factors, from manufacturing and shipping billions of agents to ensuring Rich countries do not monopolize The world’s vaccine supply, and it is essential that the vaccine is actually vaccinated into people’s arms.
The chart and map below will be updated to show the latest data on the largest vaccination program in the history of the United States and the world.
There are significant differences between states in the speed at which vaccines are provided to people.
The first two vaccines Officially recognized in order to Emergency use In the United States, developed by the company Pfizer/BioNTech with Modern, Designed to be administered in two divided doses several weeks apart.This Johnson & Johnson The vaccine authorized for use in late February requires only one dose. Therefore, vaccinating everyone in the United States will ultimately mean 100 to 200 doses of vaccine for every 100 people in each state and territory — or 330 million to 660 million doses of vaccine for the entire country.it is Huge logistics challenge.
With the Biden administration taking over and committing to strengthen the federal government’s coordination of vaccine launches, the number of vaccines injected daily has steadily increased, reaching a peak of over 3 million doses per day in April. In May, faced with a sharp drop in the number of shots, Biden announced New strategy The aim is to vaccinate difficult-to-reach communities, shifting from mass vaccination centers to more mobile clinics and pharmacies for appointments.Despite this, there are still concerns that vaccination campaigns are causing poverty people with Community of color behind.
Search or browse this table to see how your state or territory has performed these key vaccine initiatives.
Vaccine rollout schedule
This chart shows the number of vaccines vaccinated per 100 people in each state since the beginning of 2022. The first three states and the national figures of the United States are highlighted. Enter the name of any other state or U.S. territory in the search bar and select Add to chart.
This chart shows the daily dose of vaccine that people across the country have received since the beginning of 2022. The data peaks due to reporting lag, and the line showing the 7-day rolling average for a given dose more clearly indicates whether the rollout is accelerating or slowing.
Countries launch vaccines
More countries appear on this map, showing vaccine doses per 100 people, because these numbers are more widely reported.
To date, most countries with the highest vaccination rates have very small populations. The United States leads most other major countries in terms of vaccine launch. Search or browse this table to see what’s happening in each country.
Vaccine rollout schedule
This chart shows the number of vaccines vaccinated per 100 people in each country since the beginning of 2022. Enter the name of any country in the search bar, and then choose to compare its timeline with the United States and the three other leading countries in global vaccine promotion. Only countries that have started vaccination campaigns will appear.
This chart shows the daily vaccination doses reported to people around the world. Because of the spikes caused by the reporting lag, the line showing the 7-day rolling average for a given dose provides a clearer picture of whether the roll-out is accelerating or slowing.
Current status of leading vaccines
This table records the status of the leading COVID-19 vaccines, shows the authorizations for use in the United States and other selected markets, and the prices in the purchase agreement information UNICEF compilation, Where available.
Pfizer/BioNTech and Moderna’s vaccines, clinical trial results show that they are more than 90% effective In terms of disease prevention, based on new technology It provides an RNA sequence that enables our own cells to produce viral proteins to trigger an immune response.
The disadvantage is that these vaccines are more expensive than vaccines made by splicing the genetic material of the coronavirus into a disabled version of another virus, such as the vaccine produced by the British-Swedish company AstraZeneca. Based on Oxford University research, Johnson & Johnson, And Russian Gamalian Institute.
Other leading vaccines are based on inactivated versions of the coronavirus, which is a long-term method of making vaccines, or protein subunits derived from the virus.
Jeremy Singer-Vine reported on this story.